Phase 1 Multiple Sclerosis Trial, Recruiting NCT04699747 Sponsor: Massachusetts General Hospital Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Phase 1 Multiple Sclerosis Trial, Recruiting

NCT04699747
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are aged 18 or older but under 65 years old
  • People who are able to understand the study information and agree to take part before any study procedures begin

Who may not be able to join:

  • People who have a known structural brain condition, such as a brain tumor or a previous stroke
  • People who have a reason they cannot safely have an MRI or PET scan, including any of the following:
  • People who wear a life vest
  • People who have an implanted heart device, such as a pacemaker or defibrillator (ICD)
  • People who have a metal fragment or foreign object in their body
  • People who have any other device or implant that is not safe to use with an MRI, such as an insulin pump, joint replacement, hearing aid, cochlear implant, or permanent contraceptive devices
  • People who experience severe claustrophobia (extreme fear of enclosed spaces)
  • People who have a reason they cannot receive the contrast dye called Dotarem, including a history of kidney disease or severely reduced kidney function, a history of diabetes, lupus, multiple myeloma, a condition called nephrogenic systemic fibrosis, or other serious health conditions (confirm with trial site)
  • People who have had an allergic or hypersensitive reaction to Dotarem or any gadolinium-based contrast agent in the past
  • People whose radiation exposure from medical procedures in the past 12 months has already reached or exceeded the Radiology Department's current safety limit of 50 mSv
  • Women who have a positive pregnancy test, are currently breastfeeding, or where the possibility of pregnancy cannot be ruled out before the study dose is given
  • People who are unable to provide written consent to participate
  • People who have a significant acute or unstable physical or psychiatric condition that the study investigators determine would make participation unsafe or unsuitable, based on medical history or a physical examination
  • People whose blood test results are considered by the study investigators to be incompatible with safe participation in the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: (617) 643-4574

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
25 March 2021
Est. completion
30 November 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Binding of 18-F 3F4AP in the brain of healthy volunteers and multiple sclerosis subjects; Number of participants with adverse events related to tracer administration as assessed by CTCAE v4.0

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov